LUMOS PHARMA, INC.

AUSTIN, TX How do I update this listing?

Lumos Pharma is based out of Austin. NewLink Genetics Corporation is a late-stage, biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Their portfolio includes both off-the-shelf��� biologic and small-molecule immunotherapy product candidates intended to address large, unmet oncology indications, including treatment of pancreatic cancer, non-small cell lung cancer (NSCLC), and melanoma. They believe their technologies may also be useful in the field of infectious disease.Whalewisdom has at least 2 13D filings, 3 13G filings, and 189 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2011-09-22. The notice included securities offered of Equity

Create Alert

Contact Info

lumos pharma, inc.
4200 MARATHON BLVD.
AUSTIN TX    78756

Business Phone: 512-215-2630
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2011-09-22 D/A BIOTECHNOLOGY Equity 12,760,000 12,760,000 0
2011-08-17 D/A BIOTECHNOLOGY Equity 10,360,687 10,360,687 0
2011-06-03 D BIOTECHNOLOGY Equity 250,000 250,000 0
2011-01-31 D/A BIOTECHNOLOGY Equity 8,634,500 8,634,500 0
2011-01-21 D BIOTECHNOLOGY Equity 10,360,687 10,360,687 0
2010-12-07 D BIOTECHNOLOGY Equity 7,319,375 7,319,375 0
2009-07-28 D BIOTECHNOLOGY Equity 7,500,000 7,500,000 0
2009-07-28 D/A BIOTECHNOLOGY Equity 30,000,000 20,714,105 9,285,895
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
CHARLES LINK, M.D. subscription required
    EXECUTIVE OFFICER DIRECTOR
DAVID J. LUNDQUIST subscription required
    DIRECTOR
ERNEST TALARICO, III subscription required
    DIRECTOR
GORDON H. LINK subscription required
    EXECUTIVE OFFICER
JOSEPH SALURI subscription required
    DIRECTOR
KENNETH LYNN subscription required
    EXECUTIVE OFFICER
NICHOLAS VAHANIAN, M.D. subscription required
    EXECUTIVE OFFICER
PAUL EDICK subscription required
    DIRECTOR
SARAH J. ALEXANDER, M.D. subscription required
    DIRECTOR
TOM RAFFIN, M.D. subscription required
    DIRECTOR

Elevate your investments